Search alternatives:
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
Showing 421 - 440 results of 106,052 for search '(( 5 ((((ng decrease) OR (nn decrease))) OR (a decrease)) ) OR ( e mean decrease ))', query time: 1.28s Refine Results
  1. 421
    Astrocytes express a ligand for NKp44 and increasing concentrations of HIV 3S peptide decreases its expression.

    Astrocytes express a ligand for NKp44 and increasing concentrations of HIV 3S peptide decreases its expression. by Kelly E. Bowen (4857370)

    Published 2018
    Save to List
    Saved in:
  2. 422
    Increased AHP Amplitude and decreased AP firing in the presence of kainic acid is dependent on the GluR5 subunit.

    Increased AHP Amplitude and decreased AP firing in the presence of kainic acid is dependent on the GluR5 subunit. by Barbara Gisabella (330774)

    Published 2013
    “…UBP296 failed to induce any electrophysiological changes in control rats (<b>A</b>–<b>E</b>). <b>E</b>, This panel shows representative traces recorded before and after application of UBP296 in PICRO versus SAL rats. …”
    Save to List
    Saved in:
  3. 423
    NSE-apoE4, but not GFAP-apoE4, mice have decreased spine density in the auditory cortex at 19–21 months of age.

    NSE-apoE4, but not GFAP-apoE4, mice have decreased spine density in the auditory cortex at 19–21 months of age. by Sachi Jain (108277)

    Published 2013
    Save to List
    Saved in:
  4. 424
    FGF10 dose dependency of the cellular response in E13.5 (black) and E14.5 (blue) epithelium.

    FGF10 dose dependency of the cellular response in E13.5 (black) and E14.5 (blue) epithelium. by Hisako Takigawa-Imamura (3175320)

    Published 2024
    Save to List
    Saved in:
  5. 425
    Increased body weight and decreased expansion of pro-inflammatory CD4+ T-cells from blood in Tg-HD5 rats.

    Increased body weight and decreased expansion of pro-inflammatory CD4+ T-cells from blood in Tg-HD5 rats. by Osiris Marroquin Belaunzaran (224031)

    Published 2015
    Save to List
    Saved in:
  6. 426
    Comparison of the MMP in HL-1 cells exposed to LG, NG, HG and IHG between short- (12h) and long-time (72h) glucose treatment.

    Comparison of the MMP in HL-1 cells exposed to LG, NG, HG and IHG between short- (12h) and long-time (72h) glucose treatment. by Patrick Mordel (17020879)

    Published 2023
    Save to List
    Saved in:
  7. 427
    The m<sup>6</sup>A peak of 3’UTR of TLR4 mRNA decreases significantly in METTL14-knockdown PK-15 cells.

    The m<sup>6</sup>A peak of 3’UTR of TLR4 mRNA decreases significantly in METTL14-knockdown PK-15 cells. by Jing Chen (4762)

    Published 2024
    Save to List
    Saved in:
  8. 428
    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells.

    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

    Published 2014
    Save to List
    Saved in:
  9. 429
    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells.

    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

    Published 2014
    Save to List
    Saved in:
  10. 430
    Resveratrol decreases CYP17A1 and CYP21A2 protein expression.

    Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

    Published 2017
    “…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”
    Save to List
    Saved in:
  11. 431
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 432
    <i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort

    <i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

    Published 2014
    Save to List
    Saved in:
  13. 433
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 434
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 435
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 436
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 437
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 438
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 439
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 440
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: